z-logo
open-access-imgOpen Access
Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib
Author(s) -
Dimitri Anzellini,
GIANLUCA ARCANGELI,
SERGIO DEL BIANCO
Publication year - 2022
Publication title -
cancer diagnosis and prognosis
Language(s) - English
Resource type - Journals
ISSN - 2732-7787
DOI - 10.21873/cdp.10080
Subject(s) - olaparib , parp inhibitor , endometrial cancer , medicine , oncology , cancer research , malignancy , serous fluid , chemotherapy , poly adp ribose polymerase , carcinoma , clear cell carcinoma , adenocarcinoma , ovarian cancer , cancer , polymerase , biology , biochemistry , gene
Cancer of the endometrium is the most common gynecologic malignancy in developed countries and the second most common in developing countries. Endometrioid tumors tend to have a favorable prognosis and typically present at an early stage with abnormal uterine bleeding. Clear cell carcinoma as well as serous endometrial carcinoma are associated with a poorer prognosis. Patients with metastatic endometrial cancer are treated with systemic therapy either following surgery or as primary therapy. As far as second-line chemotherapy is concerned, there are no general agreements on the chemotherapy to be used. Furthermore, to the best of knowledge, there are no studies on the use of poly (ADP ribose) polymerase (PARP) inhibitors in endometrial cancer even in BRCA mutated tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here